EMA Authorised: Zolgensma (onasemnogene abeparvovec) — Novartis Europharm Limited

View source ↗

Summary

The EMA has authorised Zolgensma (onasemnogene abeparvovec) from Novartis Europharm Limited with conditional approval for spinal muscular atrophy as an orphan m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Status: Authorised. Therapeutic area: Muscular Atrophy, Spinal. MAH: Novartis Europharm Limited. Decision date: 23/06/2026. Conditional approval. Orphan medicine